Medtronic gains attention as renal denervation optimism, revenue growth, cardiac care, and diabetes technology reshape its ...
Research presented at the American Diabetes Association's 71st Scientific Sessions (ADA) this week adds to the clinical evidence for Medtronic's sensor-augmented insulin pump therapy for improved ...
DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the first patient implants in the TITAN 2 pivotal study that will evaluate ...
Minimally invasive treatment for BPH preserved sexual function, eliminated blood transfusions and reduced recovery time, British study finds Two common treatment options for benign prostatic ...
MINNEAPOLIS - Medtronic, Inc. today announced CE (Conformité Européenne) Mark receipt and the European launch of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P. The Viva CRT-P is ...
Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation (DBS) Therapy for refractory epilepsy patients. Medtronic DBS therapy ...
In 2006 executives within the Neurological division at Medtronic were trying to determine how to get a new innovative deep brain stimulation therapy to a standard of care. Medtronic had been very ...
New Investigational Device Aims to Expand Access to Therapy for Patients with Incontinence; Underscores Medtronic's Leadership as Only Company to Offer Neuromodulation Options for Incontinence DUBLIN, ...
At Samsung Developer Conference 2019 today, Medtronic and Samsung showed off a Galaxy smartphone app, Patient Programmer, that allows patients to manage their own therapy for Parkinson’s disease.
Medtronic (NYSE:MDT) has completed its $550 million acquisition of Scientia Vascular. The deal brings specialized guidewires ...
InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, ...
DUBLIN, Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results